이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

OvariAn Secretome and Integrated HealthSpan (OASIS)

2026년 11월 19일 업데이트: Dr. Abigail Goshen, Sheba Medical Center

A Three-Part Study of Ovarian Aging, Circulating Molecular Signatures, and Multidomain Healthspan in Women

The OASIS study aims to identify and characterize circulating molecular signatures associated with ovarian aging, and to determine how these signatures relate to multidomain healthspan during the menopausal transition. The study consists of three parts. Part 1 is a retrospective analysis of existing clinical data and stored biospecimens from approximately 500 women aged 50-85 years. Part 2 is a prospective cohort of 300 women aged 40-50 years who will undergo comprehensive clinical, gynecological, and molecular assessments over 24 months, followed by individualized medical management based on their clinical findings. Part 3 (PRISM) is a nested substudy involving up to 30 women from the prospective cohort who will undergo intensive hormonal and ultrasound monitoring across a single menstrual cycle.

연구 개요

상태

아직 모집하지 않음

정황

상세 설명

Background and Purpose:

The menopausal transition is a biologically dynamic period involving changes in ovarian reserve, endocrine function, and morphology that parallel shifts in body composition, bone, cardiovascular, metabolic, sleep, and cognitive health. Because conventional endocrine markers (estradiol, FSH, LH, AMH) do not provide a complete molecular readout of ovarian biology across this transition, OASIS will establish an integrated biological framework linking ovarian aging with systemic molecular physiology using advanced multi-omics profiling.

Part 1: Retrospective OASIS Biobank Cohort This phase includes approximately 500 women aged 50-85 years who previously participated in research at Sheba Medical Center and signed the applicable Biobank consent. The study utilizes existing coded demographic, clinical, and lifestyle data, alongside stored plasma samples. No new patient contact or procedures are required.

Part 2: Prospective OASIS Cohort

This phase will enroll 300 women aged 40-50 years. Participants will complete three study visits over two years:

Baseline (Month 0) and Month 12: Comprehensive multidomain clinical assessment, standardized gynecological evaluation, transvaginal ultrasound (uterus and ovaries), and biospecimen collection for clinical testing and biospecimen banking.

Month 24: A limited follow-up visit including a medical update, the Menopause Rating Scale (MRS) and selected questionnaires, fasting reproductive-hormone testing (including AMH), biospecimen collection, and a gynecological/ultrasound assessment.

Clinical Management: Following the baseline visit, participants will receive their validated clinical results, a medical summary, and individualized recommendations. Management is tailored to the participant's specific clinical findings and may include lifestyle modifications and consideration of Hormone Replacement Therapy/Menopausal Hormone Therapy (HRT/MHT) when clinically indicated.

Part 3: PRISM Nested Intensive Substudy (Precision Reproductive Imaging and Secretome Monitoring) Participation in PRISM is optional and requires separate informed consent. Up to 30 women from Part 2 may participate in up to four additional visits, separate from the main OASIS baseline visit, during a single menstrual cycle.

연구 유형

관찰

등록 (추정된)

800

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Tel Aviv
      • Ramat Gan, Tel Aviv, 이스라엘, 5262000
        • Sheba Medical Center
        • 연락하다:
          • Abigail Goshen
          • 전화번호: 972542270050
        • 수석 연구원:
          • Abigail Goshen, PhD
        • 수석 연구원:
          • Lauren Petrick, PhD
        • 부수사관:
          • Yaron Rabinovici, Dr

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

40년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

여성

샘플링 방법

비확률 샘플

연구 인구

Part 1, retrospective biobank cohort: women aged 50 years and above Parts 2 and 3, prospective main cohort and nested PRISM cohort: women aged 40-50 years

설명

Inclusion Criteria:

  • Women aged 50-85 years at enrollment (for part 1 retrospective study). or
  • Women aged 40-50 years at enrollment (for part 2 prospective study).
  • Able to understand the study information and provide written informed consent.
  • Able and willing to complete the study assessments and follow-up visits.

Part 3 (PRISM substudy) specific criteria:

  • Natural, regular menstruation.
  • Reported menstrual-cycle length of 21-35 days.
  • Willing and able to attend four additional blood-draw and transvaginal ultrasound visits across one menstrual cycle.
  • Signed separate PRISM informed consent.
  • Not using oral contraceptives, other hormonal contraceptives, menopausal hormone therapy, or another hormonal treatment at PRISM enrollment.

Exclusion Criteria:

  • A former diagnosis of significant cognitive reduction (MoCA score <24).
  • Former diagnosis of a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, or Lewy body dementia.
  • Former diagnosis of psychiatric disease.
  • Underwent chemotherapy or radiation therapy in the past two years.

Part 3 (PRISM substudy) specific criteria:

  • Failure to meet the PRISM inclusion criteria.
  • Unwillingness or inability to sign the PRISM consent.
  • Irregular cycle or reported cycle length outside 21-35 days.
  • Current hormonal contraceptive, menopausal hormone therapy or other hormonal treatment.
  • Inability or unwillingness to undergo repeated blood draws.
  • Inability or unwillingness to undergo transvaginal ultrasound.
  • A medical condition that, in the investigator's judgment, makes participation unsafe or unsuitable.
  • A medical, technical, or logistical reason that precludes reliable completion of the substudy.
  • Pregnancy, breastfeeding, initiation of hormonal treatment, or a significant medical change during PRISM must be reported to the study team and may lead to discontinuation at the Principal Investigator's discretion.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: OTHER

코호트 및 개입

그룹/코호트
Part 1: Retrospective Biobank Cohort

500 women aged 50 years and older with available clinical data and stored biospecimens from the Sheba Biobank. Evaluation is limited to retrospective data extraction and molecular analysis.

Part 2: Prospective Main Cohort

300 women aged 40-50 years undergo longitudinal clinical, multidomain, and gynecological assessments at Baseline, Month 12, and Month 24, and provide biosamples. Participants receive individualized clinical management (including potential HRT/MHT) based on the clinical findings.

Part 3: PRISM Nested Substudy

Up to 30 women co-enrolled from Part 2. Participants undergo intensive repeated measures (transvaginal ultrasound and blood sampling for hormone/molecular analysis) across up to four visits during a single menstrual cycle to assess short-term longitudinal changes.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Reproductive hormone concentrations
기간: Baseline, 12 months, 24 months

The concentrations of anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone will be measured in blood samples.

Baseline, 12 months, 24 months
Antral Follicle Count (AFC)
기간: Baseline, 12 months, 24 months

The total number of antral follicles in both ovaries will be assessed using transvaginal ultrasound.

Baseline, 12 months, 24 months
Total ovarian volume
기간: Baseline, 12 months, 24 months

Ovarian volume in milliliters will be measured using transvaginal ultrasound. Total ovarian volume will be calculated based on measurements of both ovaries.

Baseline, 12 months, 24 months
Number of participants with abnormal ovarian or adnexal ultrasound findings
기간: Baseline, 12 months, 24 months

The number and proportion of participants with abnormal ovarian morphology, ovarian cysts, or other abnormal adnexal findings identified by transvaginal ultrasound will be recorded.

Baseline, 12 months, 24 months
Circulating ovarian-associated molecular signature
기간: Baseline, 12 months

Plasma protein levels will be assessed using high-throughput proteomic profiling with the Olink Explore HT platform to characterize circulating molecular signatures associated with ovarian function.

Baseline, 12 months
Montreal Cognitive Assessment (MoCA) score
기간: Baseline, 12 months

Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

Baseline, 12 months
Apnea-Hypopnea Index (AHI)
기간: Baseline, 12 months

Sleep apnea severity will be assessed by measuring the Apnea-Hypopnea Index (AHI), defined as the number of apnea and hypopnea events per hour of sleep.

Baseline, 12 months
Glycated hemoglobin (HbA1c)
기간: Baseline, 12 months

Glycemic control will be assessed by measuring the percentage of glycated hemoglobin (HbA1c) in blood samples.

Baseline, 12 months
DXA-derived body composition
기간: Baseline, 12 months

Body composition will be assessed using dual-energy X-ray absorptiometry (DXA), including measurements of fat mass and lean mass (kg).

Baseline, 12 months
Bone mineral density (BMD)
기간: Baseline, 12 months

Bone mineral density (BMD) will be measured using dual-energy X-ray absorptiometry (DXA) at the lumbar spine, femoral neck, and total hip. Results will be reported in g/cm².

Baseline, 12 months
Handgrip strength
기간: Baseline, 12 months

Physical function will be assessed by measuring handgrip strength using a calibrated hand dynamometer. Results will be reported in kilograms (kg).

Baseline, 12 months
Pulse wave velocity (PWV)
기간: Baseline, 12 months

Arterial stiffness will be assessed by measuring pulse wave velocity (PWV). Results will be reported in meters per second (m/s).

Baseline, 12 months
Within-woman changes in reproductive endocrine measures
기간: Up to four sampling time points during the first month of the study

Serial measurements of AMH, FSH, LH, estradiol, and progesterone concentrations in blood samples will be performed to assess short-term hormonal fluctuations within participants.

Up to four sampling time points during the first month of the study

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Abigail Goshen, PhD, Sheba Medical Center

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 2일

기본 완료 (추정된)

2029년 11월 1일

연구 완료 (추정된)

2030년 5월 1일

연구 등록 날짜

최초 제출

2026년 10월 22일

QC 기준을 충족하는 최초 제출

2026년 11월 19일

처음 게시됨 (실제)

2026년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 19일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 3577-26-SMC
  • OD-2026001 (기타 보조금/기금 번호: Nuttall Women's Health (NWH))

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .